短效胰岛素市场－全球产业规模、份额、趋势、机会、预测：按药物、应用、地区和竞争对手划分，2021-2031年

全球短效胰岛素市场预计将从 2025 年的 81.6 亿美元成长到 2031 年的 104.9 亿美元，复合年增长率为 4.27%。

此类治疗方案是一种重要的餐前荷尔蒙替代疗法，旨在模拟餐后人体自然分泌的胰岛素，从而调节血糖值。推动这一领域发展的主要因素是全球糖尿病盛行率和肥胖率的上升，这两者都需要有效的血糖控制来预防严重的健康併发症。根据国际糖尿病联盟（IDF）预测，到2024年，全球20至79岁的糖尿病患者将达到约5.89亿，这意味着不断增长的患者群体对可靠的治疗性介入的需求将持续而迫切。

然而，胰岛素生产高成本以及产品核可的严格监管要求严重阻碍了市场扩张。这些经济和法律障碍往往造成患者在取得和负担能力方面的不平等，尤其是在医疗资源有限的中低收入地区。这些挑战有效地限制了这些关键治疗方法的普及，并对主要成长市场的患者依从性产生负面影响，阻碍了该行业充分利用全球对糖尿病管理解决方案日益增长的需求。

市场驱动因素

随着原厂生物製剂专利陆续到期，经济实惠的生物类似胰岛素的引进和广泛应用正在推动全球短效胰岛素市场的变革。这项转变将在已开发经济体和对价格敏感的新兴经济体中引发激烈的价格竞争，从而扩大患者的用药范围。这将缓解医疗系统的财政压力，同时加速先前因成本障碍而难以获得治疗的人群的用药成长。百康生物製剂公司2024年10月发布的财报便是这项变革的成功例证。该财报显示，其生物相似药产品组合（包括其主要胰岛素产品）的销售额年增19%。这凸显了价格亲民的替代疗法快速的市场渗透率和商业性可行性。

同时，胰岛素输注装置和技术的进步透过提高给药的准确性和便利性，进一步推动了市场成长。智慧胰岛素笔和自动胰岛素输注（AID）系统的整合提高了患者的依从性和血糖控制效果，确保了对相容的速效胰岛素製剂的稳定需求。这些技术综效的影响在Inslet截至2024年11月的财年财务表现中得到了清晰体现，其销售额增长了25.7%，达到5.439亿美元，这主要得益于无导管胰岛素帮浦的普及。此外，诺和诺德报告称，2024年前九个月的胰岛素产品销售额成长了10%，反映了这些重要疗法在全球的持续应用。

市场挑战

全球短效胰岛素市场面临的主要阻碍因素是高昂的生产成本和严格的监管要求。胰岛素产品的研发涉及复杂且资本密集的生物过程，必须严格遵守世界卫生组织制定的安全通讯协定和品质标准。这些严格的合规要求需要对专业设施和技术专长进行大量投资，从而为生产成本设定了较高的下限。这使得製造商无法在不损害财务永续性的前提下，大幅降低成本以在价格敏感的发展中地区扩大销售。

因此，这些经济和法律障碍直接限制了患者获得治疗的机会，并限制了关键成长地区的市场获利能力。不断上涨的零售价格超出了中低收入国家个人和医疗系统的负担能力，导致治疗资源不足。世界卫生组织（世卫组织）预测，到2024年，全球超过50%的糖尿病患者将无法获得治疗，而造成如此巨大差距的主要原因是低收入地区缺乏价格合理的胰岛素和基本医疗保健服务。这场普遍存在的治疗费用危机正在降低患者的留存率，并阻碍市场充分满足日益增长的全球患者群体的需求。

市场趋势

吸入式短效胰岛素製剂的进步正在革新市场，为传统的餐后注射提供了一种非侵入性的替代方案。这一趋势旨在透过采用特殊颗粒工程技术的肺部给药系统，实现与生理胰岛素分泌相媲美的超快速吸收动力学，从而提高患者的生活品质和用药依从性。这些创新製剂的商业性吸引力体现在Mankind公司截至2024年11月的财年财务表现中，其旗舰产品Afrezza的销售额同比增长12%至1500万美元，显示糖尿病患者群体对无针治疗方案的持续需求。

同时，转向超速效胰岛素类似物代表血糖管理领域的重大进步，旨在消除标准速效产品中存在的给药与起效之间的时间延迟。透过使用新型辅料重新配製现有分子以加速吸收，製药研发人员正在帮助患者在更接近餐前的时间给药，从而改善餐后血糖控制。该产品类型在全球产品系列中继续保持强劲的市场份额，诺和诺德公司报告称，其超速效製剂Fiaspi在2024年第三季度的销售额达到3.94亿丹麦克朗，这证实了药物动力学优化的胰岛素在现代治疗流程中仍然具有重要意义。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球短效胰岛素市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过药物（Apidra、Novolog、 Humalog、Novolin 等）
  • 依用途（1 型糖尿病、2 型糖尿病）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美短效胰岛素市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲短效胰岛素市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区短效胰岛素市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲短效胰岛素市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲短效胰岛素市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球短效胰岛素市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novo Nordisk AS
• Sanofi SA
• Eli Lilly & Co
• Biocon Ltd
• Wockhardt Ltd
• Boehringer Ingelheim International GmbH
• Julphar Pharma Inc
• United Laboratories International Holdings Limited
• Tonghua Dongbao Pharmaceutical Co. Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Short-Acting Insulin Market is projected to expand from USD 8.16 billion in 2025 to USD 10.49 billion by 2031, achieving a compound annual growth rate of 4.27%. This therapeutic category functions as a vital prandial hormone replacement, designed to regulate blood glucose levels by mimicking the body's natural insulin release immediately following food ingestion. The primary catalyst for this growth is the escalating global incidence of diabetes mellitus alongside rising obesity rates, both of which necessitate effective glycemic control to prevent severe health complications. According to the International Diabetes Federation, approximately 589 million adults aged 20 to 79 were living with diabetes worldwide in 2024, creating an urgent and sustained demand for reliable therapeutic interventions across an expanding patient demographic.

However, market expansion is significantly impeded by the high costs associated with insulin manufacturing and the stringent regulatory requirements necessary for product approval. These economic and legislative hurdles often create disparities in access and affordability, particularly within low-to-middle-income regions where healthcare resources are limited. Such challenges effectively restrict the widespread adoption of these critical treatments and negatively impact patient adherence rates in key growth markets, preventing the sector from fully capitalizing on the rising global need for diabetes management solutions.

Market Driver

The introduction and adoption of cost-effective biosimilar insulins act as a transformative driver for the Global Short-Acting Insulin Market, particularly as patents for originator biologics expire. This transition fosters intense price competition and broadens patient access in both developed nations and price-sensitive emerging economies, alleviating financial pressure on healthcare systems while accelerating volume uptake among populations previously constrained by cost barriers. The success of this shift is highlighted by Biocon Biologics, which reported a 19% year-over-year revenue increase in its biosimilars portfolio, including key insulin assets, in its October 2024 earnings update, underscoring the rapid market penetration and commercial viability of these affordable therapeutic alternatives.

Concurrently, advancements in insulin delivery devices and technology are further propelling market growth by enhancing the precision and convenience of administration. The integration of smart insulin pens and automated insulin delivery (AID) systems improves patient adherence and glycemic outcomes, thereby securing consistent demand for compatible fast-acting insulin formulations. The impact of this technological synergy is evident in Insulet Corporation's November 2024 financial results, where revenue surged by 25.7% to $543.9 million driven largely by tubeless pump adoption. Additionally, Novo Nordisk reported a 10% growth in insulin product sales during the first nine months of 2024, reflecting sustained global usage of these essential therapeutics.

Market Challenge

A substantial restraint on the global short-acting insulin market is the prohibitive cost of manufacturing combined with stringent regulatory requirements. Developing insulin products involves complex, capital-intensive biological processes that must strictly adhere to safety protocols and quality standards established by international health authorities. These rigorous compliance obligations necessitate significant investment in specialized facilities and technical expertise, creating a high production price floor that prevents manufacturers from aggressively lowering costs to capture volume in price-sensitive developing regions without compromising their financial sustainability.

Consequently, these economic and legislative barriers directly limit patient access and restrict the market's revenue potential in critical growth territories. High retail prices often exceed the financial capabilities of individuals and healthcare systems in low-to-middle-income countries, leading to suboptimal treatment uptake. According to the World Health Organization, more than 50% of people living with diabetes worldwide were not receiving treatment in 2024, a significant gap largely attributed to the lack of access to affordable insulin and essential care in lower-income settings. This widespread affordability crisis reduces patient adherence and prevents the market from fully serving the expanding global patient population.

Market Trends

Advancements in inhalable short-acting insulin solutions are driving a significant market shift by offering a non-invasive alternative to traditional prandial injections. This trend focuses on enhancing patient quality of life and compliance through pulmonary delivery systems that utilize specialized particle engineering to provide ultra-rapid absorption kinetics comparable to physiological insulin secretion. The commercial appeal of such innovative formulations is reflected in MannKind Corporation's November 2024 financial results, which reported a 12% year-over-year revenue increase for its flagship product, Afrezza, reaching $15 million and signaling a persistent demand for needle-free therapeutic options among the diabetes community.

Simultaneously, the transition toward ultra-rapid acting insulin analogs represents a critical evolution in glycemic management, aiming to close the time lag between administration and the onset of action found in standard rapid-acting products. By reformulating existing molecules with novel excipients to accelerate absorption, pharmaceutical developers allow patients to administer dosage closer to mealtime for improved postprandial glucose control. This product class continues to maintain a strong footprint in global portfolios, as evidenced by Novo Nordisk's report of 394 million Danish kroner in sales for its ultra-rapid formulation Fiasp during the third quarter of 2024, underscoring the sustained relevance of pharmacokinetically optimized insulins in modern treatment algorithms.

Key Market Players

• Novo Nordisk AS
• Sanofi SA
• Eli Lilly & Co
• Biocon Ltd
• Wockhardt Ltd
• Boehringer Ingelheim International GmbH
• Julphar Pharma Inc
• United Laboratories International Holdings Limited
• Tonghua Dongbao Pharmaceutical Co. Ltd.

Report Scope

In this report, the Global Short-Acting Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short-Acting Insulin Market, By Drugs

• Apidra
• Novolog
• Humalog
• Novolin
• Others

Short-Acting Insulin Market, By Application

• Type 1 Diabetes
• Type 2 Diabetes

Short-Acting Insulin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Short-Acting Insulin Market.

Available Customizations:

Global Short-Acting Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short-Acting Insulin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Apidra, Novolog, Humalog, Novolin, Others)
  • 5.2.2. By Application (Type 1 Diabetes, Type 2 Diabetes)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Short-Acting Insulin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Short-Acting Insulin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Short-Acting Insulin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Short-Acting Insulin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By Application

7. Europe Short-Acting Insulin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Short-Acting Insulin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By Application
  • 7.3.2. France Short-Acting Insulin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Short-Acting Insulin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Short-Acting Insulin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Short-Acting Insulin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By Application

8. Asia Pacific Short-Acting Insulin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Short-Acting Insulin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By Application
  • 8.3.2. India Short-Acting Insulin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Short-Acting Insulin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Short-Acting Insulin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drugs
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Short-Acting Insulin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drugs
      • 8.3.5.2.2. By Application

9. Middle East & Africa Short-Acting Insulin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Short-Acting Insulin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Short-Acting Insulin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Short-Acting Insulin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By Application

10. South America Short-Acting Insulin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Short-Acting Insulin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Short-Acting Insulin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Short-Acting Insulin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Short-Acting Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novo Nordisk AS
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi SA
• 15.3. Eli Lilly & Co
• 15.4. Biocon Ltd
• 15.5. Wockhardt Ltd
• 15.6. Boehringer Ingelheim International GmbH
• 15.7. Julphar Pharma Inc
• 15.8. United Laboratories International Holdings Limited
• 15.9. Tonghua Dongbao Pharmaceutical Co. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer